Company news

Share this article:

Avanir Pharmaceuticals has completed the sale of its antipsychotic drug FazaClo to Azure Pharma for an upfront payment of $42 million plus an additional $1.9 million in working capital adjustments. Under the deal, Avanir could receive an additional $10 million in payments in 2009 and up to $2 million in royalties. Avanir said it is using $11 million of the payments to pay down some debt. Financing from this deal should allow the company to operate through the end of the next fiscal year, Avanir said.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions